| Margins | Gross margin flat at 63%; adj. EBITDA margin 27% vs 23% |
|---|---|
| Order book | Secured microspheres and respiratory CDMO manufacturing contracts |
| Demand visibility | US CDMO +81% YoY; Europe CDMO +31%; India and RoW declining |
Growth
Revenue +23% YoY, EBITDA +53%, PAT +58% in Q2. 6M revenue +21%, 6M PAT +52%.
Outlook
No explicit guidance given. 6M FY27 capex ₹2,562 Mn; R&D ₹1,077 Mn (6% of revenue); 24 RTU bag filings.
Risks
India revenue down 42% YoY, RoW down 21% on Middle East tender delays. Europe critical injectables down 30%.
Investor Presentation filed with BSE, NSE: GLAND. Summary written with AI assistance from the document.
Gland Pharma Ltd: key numbers
- Share price
- ₹3,169.60
- Market cap
- ₹52,302 Cr
- Revenue (annual)
- ₹6,431 Cr
- Net profit (annual)
- ₹1,027 Cr
- P/E (TTM)
- 46.3×Sector 42.0×
- Promoter holding
- 45.75%-6.02% QoQ
- FII holding
- 10.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gland Pharma Ltd
All →Gland Pharma Results Update
Gland Pharma reported Q2FY27 revenue of Rs. 18,336 Mn, up 23% YoY, and PAT of Rs. 2,908 Mn, up 58% YoY. The press release accompanies its quarterly financial results filing.
Gland Pharma Q2 FY27 Results: Net Profit ₹290.8 Cr, Up 58.3% YoY
Gland Pharma Ltd reported revenue from operations of ₹1,834 Cr (+23.3% YoY) and net profit of ₹290.8 Cr (+58.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹290.8 Cr · +58.3% YoY
Gland Pharma Regulatory Approval
Gland Pharma received USFDA approval for Methylprednisolone Acetate Injectable Suspension USP in multiple vial formats. The product is bioequivalent to Pfizer's Depo-Medrol in a ~$214M US market.
Gland Pharma Management Change
Gland Pharma appointed Ajay Sahni as CEO of its wholly-owned subsidiary Gland Pharma International Pte. Ltd, effective 2 November 2026. He will lead the Cenexi business.
Gland Pharma Business Update
Gland Pharma reports that USFDA concluded an unannounced cGMP inspection at its Dundigal formulation facility with four procedural Form 483 observations. No monetary impact is stated, and corrective actions will be submitted within the stipulated period.
Gland Pharma Board Meeting Date
Gland Pharma Ltd scheduled a board meeting for November 06, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ending September 30, 2026.